NFE2L2 can inhibit fibroblast-to-myofibroblast differentiation (FMD) in IPF [53] and promote myofibroblast dedifferentiation, contributing to the reduction of fibrosis. Here, NFE2L2 is linked to idiopathic pulmonary fibrosis.